Overview

A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the safety and tolerability of AMG 167 following a single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen